Medication use patterns associated with spirometry in diagnosing COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 6, 2008, Pages 360-368

  Joo, Min J ^a,b,c   Lee, Todd A ^a,d   Au, David H ^e,f   Fitzgibbon, Marian L ^b,c   Weiss, Kevin B ^g  

^a HINES VA HOSPITAL   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g American Board of Medical Specialties   (United States)

Author keywords

Chronic Obstructive Pulmonary Disease; Diagnosis; Drug Therapy; Health Services; Professional Practice

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID; IPRATROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPIROMETRY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; GLUCOCORTICOIDS; HUMANS; IPRATROPIUM; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SENSITIVITY AND SPECIFICITY; SPIROMETRY;

EID: 65349093055     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550802522346     Document Type: Article

References (40)

1. National Heart Lung and Blood Institute. Morbidity & Mortality: 2007 Chart Book on Cardiovascular, Lung, and Blood Diseases, National Heart Lung and Blood Institute, Editor. 2007.
2. Han MK, Kim MG, Mardon R, Renner P, Sullivan S, Diette GB, Martinez FJ. Spirometryutilization for COPD: Howdo wemeasure up? Chest 2007; 132(2):403-409.
3. Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest 2006; 129(6):1509-1515. (Pubitemid 43894979)
4. Badgett RG, Tanaka DJ, Hunt DK, Jelley MJ, Feinberg LE, Steiner JF, Petty TL. The clinical evaluation for diagnosing obstructive airways disease in high-risk patients. Chest 1994; 106(5):1427-1431. (Pubitemid 24346103)
5. Buffels J, Degryse J, Heyrman J, Decramer M. Ofice spirometry signi cantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004; 125 (4): 139-149.
6. Straus SE, McAlister FA, Sackett DL, Deeks JJ. Accuracy of history, wheezing, and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease. J Gen Intern Med 2002; 17(9):684-688. (Pubitemid 35013978)
7. van Schayck CP, van Weel C, Harbers HJ, van Herwaarden CL. Do physical signs re ect the degree of air o w obstruction in patients with asthma or chronic obstructive pulmonary disease? Scand J Prim Health Care 1991; 9(4):232-238.
8. Straus SE, McAlister FA, Sackett DL, Deeks JJ. The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. JAMA 2000; 283(14):1853-1857.
9. Holleman,DR Jr., Simel DL. Does the clinical examination predict air ow limitation? JAMA 1995; 273(4):313-319.
10. National Committee for Quality Assurance (NCQA), HEDIS 2006. Health plan employer data & information set, Vol. 2, Technical speci cations. 2005, National Committee for Quality Assurance (NCQA): Washington, DC. 350.
11. American Thoracic Society and European Respiratory Society. Standards for the diagnosis and management of patients with COPD. 2004 (cited 2007 December 28); Available from: http://www.thoracic.org/sections/copd/resources/copddoc. pdf.
12. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932-946. (Pubitemid 38807371)
13. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Updated 2007). (cited 2007 December 16); Available from: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989.
14. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of uticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J, 2000; 320(7245):1297-1303. (Pubitemid 30245717)
15. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and uticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775-789. (Pubitemid 46294610)
16. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek Jr. TJ, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1):47-55. (Pubitemid 34754142)
17. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Ef cacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4(3):253-262. (Pubitemid 43824800)
18. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155(4):1283-1289. (Pubitemid 27172772)
19. Lung Health Study Research Group. Effect of inhaled triamci-nolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26):1902-1909.
20. Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 2006; 130(3):640-646.
21. Ram FS, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003; 58(7):580-584. (Pubitemid 36808127)
22. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salme-terol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112(2):336-340. (Pubitemid 27349421)
23. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(5):1087-1092. (Pubitemid 32378441)
24. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61(2):122-128. (Pubitemid 43235428)
25. Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 2006; 7:147.
26. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on air ow obstruction and resting hy-perin ation in patients with COPD. Chest 2006; 129(3):509-517.
27. Wadbo M, Lofdahl CG, Larsson K, Skoogh BE, Tornling G, Arwestrom E, Bengtsson T, Strom K. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20(5):1138-1146. (Pubitemid 35331870)
28. Lung Health Study Research Group. Effect of inhaled triamci-nolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26):1902-1909.
29. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corti-costeroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113(1):59-65. (Pubitemid 34775161)
30. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticos-teroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176(2):162-166. (Pubitemid 47057852)
31. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salme-terol/uticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(2):144-149. (Pubitemid 46115085)
32. Lee TA, Weiss KB. Fracture risk associated with inhaled corticos-teroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169(7):855-859. (Pubitemid 38402463)
33. Dales RE, Vandemheen KL, Clinch J, Aaron SD. Spirometry in the primary care setting: in uence on clinical diagnosis and management of air ow obstruction. Chest 2005; 128(4):2443-2447. (Pubitemid 41507592)
34. Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L. Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J 2006; 28(5):945-952. (Pubitemid 46331963)
35. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127(8 Pt 2):757-763. (Pubitemid 27446562)
36. Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly, Jr. JJ, Sciurba FC, Thomashow BM, Wise RA. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005; 118(12):1415.
37. Bolton CE, Ionescu AA, Edwards PH, Faulkner TA, Edwards SM, Shale DJ. Attaining a correct diagnosis of COPD in general practice. Respir Med 2005; 99(4):493-500. (Pubitemid 40347834)
38. Kaminsky DA, Marcy TW, Bachand M, Irvin CG. Knowledge and use of of ce spirometry for the detection of chronic obstructive pulmonary disease by primary care physicians. Respir Care 2005; 50(12):1639-1648. (Pubitemid 46888423)
39. Walters JA, Hansen E, Mudge P, Johns DP, Walters EH, Wood-Baker R. Barriers to the use of spirometry in general practice. Aust Fam Physician 2005; 34(3):201-203.
40. Joo MJ, Lee TA, Weiss KB. Geographic variation in chronic obstructive pulmonary disease exacerbation rates. J Gen Intern Med 2007; 22(11):1560-1565. (Pubitemid 47568691)